Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Translational oncology"
DOI: 10.1016/j.tranon.2022.101418
Abstract: In the era of value-based oncology care, stakeholders are increasingly using patient reported outcomes (PROs) to guide clinical and regulatory decisions. PROs are also included in health technology assessments to guide patient access, drug reimbursement… read more here.
Keywords: reported outcomes; nivolumab advanced; clinical trials; oncology ... See more keywords